D
espite decades of clinical experience with antibiotic use, treatment of severe infections remains a challenge for clinicians. Over the past years, two important phenomena have made even more essential the need to improve the use of presently available antibiotics and to extend the effective life of a drug: (1) the escalation in the incidence of bacteria resistant to the available antibiotics 1 and (2) the dearth of antimicrobial drugs with new mechanisms of action in development. 2 One mechanism to improve optimization of antibiotic use may be improvement of antibiotic dosing because a causal relationship is thought to exist among inappropriate dosing, clinical outcome, and the development of bacterial resistance. 3 From a clinical perspective, optimization of antibiotic use is particularly important for critically ill patients in whom early and appropriate antibiotic prescription has been shown to reduce mortality. 4 -10 The physiologic and pharmacokinetic derangements in antibiotics have been reviewed previously for patients with sepsis 11 ; however, there is an absence of guidance on rational approaches to antibiotic dosing in patients with multiple organ dysfunction syndrome (MODS) who have higher levels of sickness severity and whereby effective antibiotic therapy may be even more important to clinical outcome. The purpose of this article is to review, using examples from the literature, the key concepts likely to affect antibiotic pharmacokinetics and pharmacodynamics and to provide dose recommendations for the treatment of critically ill patients with MODS.
Search Strategy and Selection Criteria
Data were identifi ed by a systematic search in PubMed (1966-October 2010) for original articles that evaluated the variations in antibiotic pharmacokinetics and pharmacokinetics/pharmacodynamics (PK/PD) in MODS. Key words used were "sepsis" or "systemic infl ammation response syndrome" or "septic www.chestpubs.org shock" or "multiple organ failure" and "antibacterial agents" or "antibiotics" and "pharmacokinetics" or "pharmacodynamics" and "critically ill patient" or "intensive care unit" or "critical care." A total of 167 articles were returned, of which only 48 were deemed relevant for critically ill patients with MODS or some level of organ dysfunction. Numerous articles also were identifi ed through searches of the extensive fi les of the authors.
Overview of Antibiotic Physicochemistry, Pharmacokinetics, and Pharmacodynamics
The term "antibiotic" includes a variety of chemical compounds that exhibit great differences among them in terms of mechanism of action and physicochemical, pharmacokinetic, and pharmacodynamic characteristics. The uniqueness of each class makes independent study essential to provide accurate characterization of antibiotic behavior.
Physicochemistry
A simple, but useful chemical classifi cation for antibiotics is by their affi nity for water. Hydrophilic drugs predominantly distribute into intravascular and interstitial water but are unable to passively cross the lipid cellular membrane and, therefore, do not penetrate intracellularly in meaningful concentrations. Hence, their volume of distribution (Vd) is equivalent to the extracellular water and usually corresponds to a value between 0.1 L/kg and 0.3 L /kg. 11 On the contrary, lipophilic drugs can cross lipid membranes and, therefore, distribute intracellularly and into adipose tissues. Hence, the Vd of lipophilic drugs depends on the amount of adipose tissue, which generally is proportional to total body weight. 11 There are a few exceptions where this approach cannot be extrapolated, for example, in patients with increased muscle mass, as muscle tissue is highly hydrophilic and affects the Vd of lipophilic drugs to a lesser extent.
Pharmacokinetics
Pharmacokinetics is the study of the interrelationship between drug dose and variations in concentrations in plasma and tissue over time. The most relevant pharmacokinetic parameters include the following 12 
Pharmacodynamics and PK /PD
Pharmacodynamics is the study of the relationship between drug concentrations and effect. 12 The PK/PD approach seeks to establish a relationship between dosage and pharmacological effect. 12 Figure 1 represents the relationship among pharmacokinetics, pharmacodynamics, and PK/PD. Antibiotics can be categorized in three different classes depending on the PK/PD indices associated with their optimal killing activity. 13 Time-Dependent Antibiotics: Optimal activity is achieved when unbound plasma concentrations are maintained above the minimum inhibitory concen tration (MIC) of the bacteria ( ƒ T . MIC) for a defi ned fraction of the dosing interval.
Concentration-Dependent Antibiotics:
Optimal activity correlates with Cmax, quantifi ed by its ratio with the MIC of the bacteria (Cmax/MIC).
Concentration-Dependent Antibiotics With Time
Dependence: A defi ned ratio between the unbound AUC 0-24 and the MIC of the bacteria (ƒAUC 0-24 /MIC) corre lates with optimal activity.
Pathophysiology of MODS and Effect on Drug Vd and CL
Sepsis-related MODS has been defi ned as the worsening of organ function due to a severe infection such that homeostasis cannot be maintained without intervention, usually involving two or more organ systems. 14 Endotoxins have a cascade effect on the production of endogenous molecules that act on the vascular endothelium, leading to vasodilatation and transcapillary leakage of fl uid and proteins into the extracellular space. 15 Moreover, sepsis is known to produce myocardial dysfunction. 16 These hemodynamic alterations lead to sepsis-induced tissue hypoperfusion, which can affect pharmacokinetics. Because antibiotics are a group of drugs with "silent" pharmacodynamics (ie, the pharmacologic effect is not perceivable immediately after administration), it is almost impossible to assess whether therapeutic concentrations are being achieved during the early phase of therapy. Therefore, consideration of the scenarios likely to alter antibiotic pharmacokinetics and necessitate dosage adjustment are necessary to enable individualization of antibiotic therapy.
Tissue Hypoperfusion
In the fi rst stage of septic shock (warm shock), arteries dilate, decreasing peripheral arterial resistance and causing a refl ex increase in cardiac output.
Later, typical features of septic shock may appear, including a decrease in cardiac output and BP. 17 This sepsis-mediated altered blood fl ow may have important effects on drug delivery to tissues.
During the warm shock phase, hypoperfusion of vital organs (eg, brain or lung) occurs, whereas peripheral tissues and nonvital organs still receive high blood fl ow as a consequence of peripheral vasodilation and increased cardiac work. 17 Vital organs hypoperfusion can lead to suboptimal delivery of antibiotic and subtherapeutic levels at the target site during the initial stages of the infection in vital organ infections (eg, respiratory tract infections). However, a challenge for interpretation is the absence of pharmacokinetic data specifi cally targeting the effects of warm shock on drug distribution, and more research is required in this area.
Peripheral tissue hypoperfusion can occur during the second phase of septic shock as a result of the body's attempt to increase perfusion of the vital organs. 18 Because peripheral tissues frequently are the source of infection, 19 hypoperfusion can lead to a failure to attain therapeutic concentrations at the site of infection. 20 A similar scenario may be observed in patients with fl uid shifts, capillary leak, and edema. 21 In this case, despite increased movement of plasma and solutes (eg, hydrophilic antibiotics) to the extravascular compartment, drug concentrations at the target site could decrease because of a dilution effect. 21 Alternative approaches to drug administration, such as continuous or extended infusion, have been shown to reach more consistent antibiotic concentrations in tissue for time-dependent antibiotics in these scenarios and should be considered when treating infections by poorly susceptible bacteria. 22 , 23 Monte Carlo simulations can be used to this end to compare www.chestpubs.org the relative PK/PD target attainments for different dosing approaches for antibiotics, particularly for time-dependent antibiotics. These analyses have shown consistently that extended infusions ( . 3 h) or continuous infusions of time-dependent antibiotics achieve PK/PD targets more successfully than intermittent infusions ( Յ 30 min). 24 -26 Monte Carlo simulations also can be used to show the effect of renal dysfunction on the achievement of PK/PD targets. Figure 2 has been adapted from Roberts et al 22 and describes how administering the same dose of meropenem in different levels of renal dysfunction will provide different levels of achievement of PK/PD targets. Use of extended or continuous infusions in this context could serve to further increase the achievement of PK/PD targets.
Renal Dysfunction
Several factors can precipitate acute kidney injury (AKI) in critically ill patients. 27 Early identifi cation of AKI and accurate assessment of renal function are essential for daily dose adjustment of hydrophilic antibiotics. The estimations of creatinine clearance (CrCL) as a surrogate for glomerular fi ltration rate (GFR) using formulas such as Cockroft-Gault and modifi ed diet in renal disease (MDRD) must be interpreted carefully in critically ill patients because despite having well-documented clinical value in specifi c patient populations (eg, patients with chronic kidney disease), they are yet to be validated in critically ill patients. Because plasma creatinine concentrations can vary for many reasons other than renal function in these patients (eg, decreases due to immobilityrelated cachexia) and are rarely at steady state, these formulas may lead to inaccurate estimations of GFR and lead to inappropriate dose adjustments. 28 , 29 Where possible, it is preferable to use either 8-, 12-, or 24-h urinary CrCL to estimate GFR in critically ill patients. 30 -32 When using urinary CrCL, dose recommendations in the product information for estimated GFR by MDRD or Cockroft-Gault also apply. The main issue here is not the change in drug CL relative to GFR that is problematic; rather, it is how GFR is calculated. If GFR is not accurately estimated, then any dose adjustment is likely to be suboptimal.
Hepatic Dysfunction
The most common causes of liver failure in critically ill patients are infection-related cholestasis and hepatocellular injury, which occur in response to bacterial toxins and to the toxins themselves. 33 In the fi rst case, bacterial toxins and released cytokines can affect the uptake and excretion of bile by hepatocytes, leading to jaundice. In the second case, endotoxins and bacteria are phagocytized by Kupffer cells that release several hepatotoxic molecules, leading to cellular damage . 33 Hepatic dysfunction also may result from organ hypoperfusion, hemolysis, or concomitant administration of hepatotoxic drugs (eg, rifampicin). 33 , 34 Assessment of the degree of hepatic dysfunction in acute liver failure is mainly clinical and may include signs and symptoms such as elevations in liver enzymes, bilirubin, or ammonia and decreases in the concentration of liver-produced proteins (eg, albumin, a 1 -acid glycoprotein, coagulation factors). Hepatic dysfunction may impair metabolism and, therefore, lead to accumulation of hepatically cleared antibiotics. 35 , 36 A decrease in the hepatic production of albumin and a 1 -acid glycoprotein also can alter pharmacokinetics of highly protein-bound antibi otics. 25 , 37 , 38 Albumin is the most frequent drug carrier in the bloodstream. The drug-protein interaction is rapid and dynamic, and an equilibrium depends on the concentration of both drug and protein. 39 In the presence of hypoalbuminemia, a larger number of unbound drug molecules are able to distribute from the bloodstream into tissues to a larger extent than when there is normal protein binding; pharmacokinetically, this is translated into a larger Vd. 39 Furthermore, clinical management of severe hepatic failure may include renal replacement therapy (RRT) and the use of adsorbent columns for removing excess ammonia and other waste products in the blood. 40 The additive effect of these interventions and endogenous renal function on the excretion of renally cleared antibiotics has to be considered when dosing with hydrophilic antibiotics. Optimizing Initial Dosing of Antibiotics in MODS
Pharmacokinetic alterations mediated by MODS should be considered during antibiotic prescription in critically ill patients. During the initial phase of sepsis, increased Vd and CL are common, and dosing must be adjusted, 11 , 41 , 42 which has been confi rmed by two recent studies. The fi rst study, by Roberts et al, 43 was a b -lactam therapeutic drug monitoring (TDM) evaluation in critically ill patients, including patients with MODS, that found that ‫ف‬ 70% of patients did not achieve appropriate antibiotic concentrations, with requirement of 50.4% and 23.7% dose increases and decreases, respectively, on the initial phase of therapy. The second was a multicenter study by Taccone et al 44 that showed that conventional initial dosing for many b -lactams frequently used in critically ill patients was insuffi cient for achieving PK/PD targets on the fi rst day of therapy. In this study, only 28% of the patients on ceftazidime, 16% on cefepime, and 44% on piperacillin/tazobactam achieved the PK/PD targets on the fi rst day of therapy. The authors found that 40% of patients receiving piperacillin/ tazobactam had plasma concentrations of less than four times MIC within 90 min after administration.
The results of both studies are likely to be due to an increased Vd for these patients. 15 , 45 It is important to note that in the study by Taccone et al, 44 27% of the patients had AKI, and despite having been prescribed with standard non-AKI initial doses, most of them had suboptimal concentrations after the fi rst dose. In contrast, in the study by Roberts et al, 43 19% of patients had AKI (with or without dialysis requirements), and on days 2 through 5, 72% of these patients required a dose decrease. The data from both studies suggest that initial antibiotic dosing needs to account for the increased Vd that occurs in critically ill patients with MODS 15 ; therefore, higher-than-standard doses should be considered in the initial phase of therapy. This concept will be referred throughout this review as "front-loaded" dosing and especially applies to hydrophilic drugs whose Vd dramatically increases in this scenario. 22 , 23 , 46 , 47 This concept was demonstrated by Marik 46 who showed a twofold increase in the Vd of amikacin in critically ill patients with gramnegative infections. This pharmacokinetic alteration will signifi cantly affect the achievement of therapeutic peak concentrations (Cmax/MIC Ն 10). 46 Recent research also supports administration of front-loaded doses for aminoglycosides (eg, 25 mg/kg for amikacin) on the fi rst day of therapy for severe sepsis and septic shock. 48 For lipophilic drugs, front-loaded doses based on total body weight should be considered for patients with a higher proportion of adipose tissue to achieve therapeutic concentrations. 49 This is the same principle by which loading doses of drugs such as amiodarone and phenytoin are required. 50 , 51 Further, evidence supports that even the Vd of hydrophilic antibiotics is increased in obese patients due to the increased interstitial fl uid, connective tissue, and muscle mass also present in obesity. 52 , 53 Therefore, obesity must be a factor to consider for initial dosing. In this context, use of an equation that assists calculation of lean body weight should be used. 54 Table 1 provides broad recommendations for optimizing initial dosing in patients with increased Vd. Table 2 provides guidance for specifi c drugs in this scenario.
Optimizing Maintenance Dosing of Antibiotics in MODS
Maintenance dosing must be guided by drug CL. Depending on the organ systems impaired by MODS, the effect on antibiotic CL can vary widely. The most relevant organ systems that may affect pharmacokinetics (mainly renal and hepatic systems) will be considered individually. Table 1 provides general principles for maintenance dosing in renal failure, hepatic failure, and RRT. Table 2 provides guidance for specifi c drugs in these scenarios. Figure 3 summarizes the scenarios likely to alter pharmacokinetics in MODS.
Renal Dysfunction
Hydrophilic antibiotics are mostly renally cleared by glomerular fi ltration and tubular secretion. Decreased CL of these drugs is well described in renal dysfunction, and as such, dose reductions or extended dosing intervals are required to prevent drug accumulation and toxicity. 55 Dose adjustments to prevent toxicity are especially relevant for antibiotics with a narrow therapeutic window, such as glycopeptides and aminoglycosides, that can produce nephrotoxicity, and, hence, its accumulation may lead to a vicious circle of injury in the damaged kidney that may lead to greater antibiotic accumulation.
When dose reducing, it is essential to consider antibiotic pharmacodynamics to ensure that targets are still attained where possible. For instance, a more appropriate dose reduction of time-dependent antibiotics would be to reduce the dose rather than the frequency of administration as a strategy to preserve the ƒ T . MIC (eg, recommended dosing of meropenem for an estimated GFR , 15 mL/min would be a frontloaded dose of 1,000 mg to provide therapeutic concentrations followed by a maintenance dose of 500 mg every 12 h to enable continued optimization of ƒ T . MIC without toxicity). For concentration-dependent drugs, www.chestpubs.org Data are modifi ed from the product information of each particular drug. Note that the product information for many of the hydrophilic antibiotics included in the like aminoglycosides, it is suggested to prolong the interval between doses rather than to decrease the dose so that the peak concentration required for optimal bacterial killing is still achieved. 11 However, despite these theoretical recommendations, uncertainty is always present when prescribing antibiotics in patients with MODS because organ function is very likely to fl uctuate from day to day during therapy. It follows that TDM is a very useful tool to titrate antibiotic dosing in MODS. TDM is widely used with aminoglycosides and glycopeptides to ensure appro priate exposure and minimize the incidence of toxicity. 56 However, the potential and usefulness of TDM as a strategy for optimizing antibiotic doses of b -lactams (the most frequently prescribed class of antibiotics) has not yet been confi rmed. Recent research has assessed its usefulness with a broad group of critically ill patients. 43 , 44 Roberts et al 43 showed that in the maintenance phase of therapy, many patients with renal dysfunction required a dose decrease due to high concentrations (about 10 times MIC), despite empirical dose adjustment for renal dysfunction. However, some other patients with renal failure or on RRT exhibit suboptimal concentrations with this adjusted dosing, which evidences that concentrations do not depend exclusively on renal function but on various other factors.
Renal Replacement Therapy
As renal function deteriorates, waste products will accumulate, and commencement of RRT should be considered. The main determinants of CL during RRT are the modality and settings prescribed. Hemodialysis, hemofi ltration, hemodiafi ltration, and peritoneal dialysis all have different mechanisms of removing metabolic waste and have a different effect on the extent to which each drug is cleared. Other factors that determine the extraction ratio are drug molecular weight (drugs with a molecular weight greater than the pores of the fi lter membrane are not able to be removed), protein binding (only unbound molecules can be removed), drug affi nity for fi lter adsorption, whether replacement fl uid is added prefi lter or postfi lter, and the ultrafi ltration rate . 57 The implications of RRT on drug dosing have been reviewed recently, 57 and a further discussion is beyond the scope of this article. However, Table 1 provides some recommendations for dosing in RRT.
Hepatic Dysfunction
Liver impairment may have a signifi cant impact on the CL of both lipophilic and hydrophilic drugs. Lipophilic drugs may undergo metabolism in the liver to increase the hydrophilicity of the compound. The CL of hepatically eliminated drugs depends on the hepatic blood fl ow and intrinsic clearance (ie, degree of enzymatic activity). Therefore, two kinds of scenarios can be distinguished. CL of highly extracted drugs is mainly correlated with hepatic blood fl ow (eg, lidocaine), whereas in less-extracted drugs, CL is determined by intrinsic CL and degree of protein binding (eg, nitroimidazoles, fl uoroquinolones). 12 Hepatic failure may imply modifi cation of both factors, leading to decreased drug elimination, accumulation, and potential toxicity. For example, in liver failure, metronidazole oxidation by microsomes may be decreased because of reduced enzyme expression and enzymatic activity, 58 leading to potential toxicities, including seizures and peripheral neuropathy.
Other drugs may be cleared by biliary excretion, which may be substantially decreased in hepatic impairment (eg, tigecycline). A study comparing patients with different degrees of hepatic failure found that tigecycline CL was reduced by 55%, and elimination half-life was prolonged by 43% in patients with severe hepatic impairment. In this context, a dose reduction is suggested to avoid toxicity. 59 Additionally, the decreased synthesis of albumin and a 1 -acid glycoprotein in liver dysfunction, together with the transcapillary distribution of these proteins due to capillary leakage, 60 may alter the pharmacokinetics of highly protein-bound antibiotics. Hypoalbuminemia has been shown to cause signifi cant increases in the Vd and CL of drugs such as ceftriaxone (85%-95% protein bound), ertapenem (85%-95%), fl ucloxacillin (95%), and teicoplanin (90%-95%). 25 , 37 , 38 , 61 Therefore, front-loaded doses should be considered when prescribing these drugs in critically ill patients with MODS and hypoalbuminemia. 39 Initial dosing recommendations for highly bound hydrophilic antibiotics ( Table 2 ) account for this scenario. Maintenance dosing should be guided by the level of organ function and in the context of the main elimination pathways for the drug and, where possible, guided by TDM. Decreased plasma concentrations of a 1 -acid glycoprotein increase substantially erythromycin Vd (73%-81% protein bound), whereas CL decreases by 60% in the presence of metabolic impairment. 62 Other antibiotics that bind substantially to this protein include trimethoprim and the lincosamides. 63 As a fi nal consideration for organ dysfunction, it is noteworthy that critically ill patients can present with underlying comorbidities, such as chronic renal or hepatic dysfunction, unrelated to sepsis. In this case, the previously mentioned dosing principles for initial and maintenance dosing also should apply. Dose adjustments should always be made according to the degree of organ function and the estimated level of drug Vd and CL present in the patient, regardless of preexisting dysfunction. Preexisting dysfunction should only be considered as a guide to the likely level of organ function in the maintenance phase of therapy.
Conclusions
Appropriate antibiotic dosing in MODS is complex and depends on several drug-and patient-related factors. Consideration of antibiotic physicochemical and pharmacodynamic characteristics and disease-related alterations in pharmacokinetics is essential for designing dosing regimens that avoid suboptimal dosing. There are two important phases in antibiotic therapy in MODS. During the fi rst day of therapy, frontloaded dosing is required and must be guided by the www.chestpubs.org predicted Vd, which is likely to be increased in critically ill patients despite impaired organ function. From day 2 onward, maintenance dosing can be adjusted in line with the CL associated with the organ dysfunction. The requirements for dose adjustment for antibiotics should be considered individually depending on the organ system that is failing and the drug CL pathway. Because of the great variability of organ function during a septic insult, TDM should be regarded as a useful tool to individualize dosing and ensure appropriate exposure to the antibiotic. Further research on dose adjustment in MODS is required for improving patient quality of care and outcomes in this population.
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